Twice-a-Year shot could revolutionize HIV prevention for young people
NCT ID NCT07390409
Summary
This study aims to see how well a new, long-acting injectable drug called Lenacapavir works for preventing HIV in real-world settings. It will offer 3700 young people (aged 15-35) in Cape Town a choice between this new injection (given twice a year), another approved injection (given every two months), or daily oral pills. The main goal is to see which option people stick with best over 18 months and to learn the best ways to deliver these prevention choices.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DTHF Mobile Clinics
Cape Town, WC, 7925, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.